Durham, NC (PRWEB) September 04, 2012
Oncologists and all professionals involved in cancer treatment know that personalized cancer care is the wave of the future—or is it already here? To answer that question, this year's Third Annual Meeting of the Society for Translational Oncology (STO) is dedicated to the theme, "Personalizing Cancer Diagnosis and Treatment."
The meeting will be hosted by UNC Lineberger Comprehensive Cancer Center at the Rizzo Center in Chapel Hill, N.C., October 20-21, 2012. "Devoting our national meeting to personalized cancer care illustrates how far this area of research has proceeded from dream to reality," said Hy Muss, MD, Professor of Medicine and Director of the Geriatric Oncology program at UNC. "Our program presents an unparalleled lineup of leading researchers, who will discuss the impact of genetic and molecular techniques on cancer management."
The meeting includes two special lectures on translational research that is opening the way to personalized cancer care in the clinic. Charles E. Perou, PhD, May Goldman Shaw Distinguished Professor of Molecular Oncology, Professor of Genetics, Pathology and Laboratory Medicine, UNC School of Medicine, will speak on "Development and Validation of Genomic Biomarkers." Shelley Earp, MD, Lineberger Professor and Director, UNC Lineberger Comprehensive Cancer Center, will discuss "The Impact of Genomic and Signaling Research on Clinical Research."
The intensive two-day program also includes expert updates on timely topics such as using molecular markers in the clinic, management of limited metastases, new approaches to cancer imaging, aging and cancer, current issues in cancer screening, targeted therapies for hematologic malignancies, and implementing Commission on Cancer Survivorship standards.
The highlight will be the Pinedo Prize Lecture by Richard L. Schilsky, M.D., "Publicly Funded Clinical Trials and the Future of Cancer Care." Dr Schilsky, Professor of Medicine and Section Chief of Hematology/Oncology at the University of Chicago Department of Medicine, receives the 2012 Bob Pinedo Cancer Care Prize in recognition of his clinical and research leadership in the areas of gastrointestinal cancers and cancer pharmacology. His lecture will be published by STO’s official peer-reviewed journal, The Oncologist.
"We invite all oncology clinicians, researchers, NPs, PAs, nurses, trainees, and anyone involved in cancer care to join us for these stimulating presentations," said Dr Muss. "It's a great opportunity to meet and exchange ideas with your colleagues—and to get a glimpse into some of the ways personalized medicine will affect your work as it positively impacts your cancer patients."
# # #
About the Society for Translational Oncology
STO is a non-profit, tax exempt association whose mission is to speed the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology. STO brings knowledge and strategies for critical new developments in cancer treatment to the practice of the community oncologist. For more information, visit: http://www.sto-online.org.
About The Oncologist
Recognized as a premier peer-reviewed cancer medicine journal, The Oncologist, now in its seventeenth year, is devoted to physicians entrusted with the care of cancer patients. The Oncologist is the official publication of the Society for Translational Oncology. For more information, visit: http://www.theoncologist.com.
About UNC Lineberger
The UNC Lineberger Comprehensive Cancer Center continues to thrive as one of the nation’s premier matrix comprehensive centers. One year after achieving an “exceptional” rating in its National Cancer Institute review, the Center continues to grow. Directed by Dr. Shelley Earp, Lineberger comprises more than 320 faculty members from across a great state university. These individuals, along with extraordinary support from the institution and the State, make the Center one of the best places to train students and postdoctoral fellows and perform integrated basic, population, translational, and clinical research. For more information, please see http://www.unclineberger.org.